

**5-Minute Journal Club: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays in the Treatment of Cancer — Issue 1, Colorectal Cancer****THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.**

1. Which of the following statements best characterizes survival outcomes by circulating tumor DNA (ctDNA) status for patients in the molecular residual disease (MRD) window after surgery for colorectal cancer (CRC) in the **CIRCULATE-Japan GALAXY** study?
  - a. ctDNA positivity was associated with a numerical but nonsignificant detriment to disease-free survival (DFS)
  - b. ctDNA positivity was associated with statistically inferior DFS
  - c. ctDNA positivity was associated with a numerical but nonsignificant detriment to overall survival (OS)
  - d. ctDNA positivity was associated with statistically inferior OS
  - e. Both a and c
  - f. Both b and d
2. In the prospective **BESPOKE CRC** study evaluating ctDNA testing for patients with Stage II/III CRC, did the assay results influence clinician treatment decisions regarding adjuvant therapy?
  - a. Yes, for 1/10 of clinicians
  - b. Yes, for 1/6 of clinicians
  - c. Yes, for 1/3 of clinicians
  - d. No
3. In the prospective **BESPOKE CRC** study, adjuvant chemotherapy was predictive of DFS benefit in which patient population?
  - a. ctDNA-negative
  - b. ctDNA-positive
  - c. Both a and b
  - d. Neither a nor b
4. In the prospective **BESPOKE CRC** study, which of the following factors was predictive of better outcomes with adjuvant chemotherapy?
  - a. ctDNA negativity at baseline
  - b. ctDNA clearance by month 3
  - c. ctDNA clearance by month 6
  - d. Both a and b
  - e. Both b and c
  - f. All of the above